The Latest Blogs from Agilex Biolabs

Author By Agilex BiolabsPosted on
This webinar examines the hot topics in immunoassay bioanalysis for biotechs navigating the immunogenicity and biomarker requirements for clinical trials. Join the discussion with panelists from Agliex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, and B2S Life Sciences, a biotherapeutic enablement company advancing improved analytical methods and outcomes for developers of biotherapeutic drugs and diagnostics

Author By Agilex BiolabsPosted on
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced the purchase of leading biolab TetraQ, based out of the University of Queensland.
Agilex Biolabs CEO Jason Valentine said the Board and senior management at Agilex Biolabs were extremely pleased with the purchase of such a high-calibre bioanalytics company.
“TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services,” he said.
Agilex Biolabs CEO Jason Valentine said the Board and senior management at Agilex Biolabs were extremely pleased with the purchase of such a high-calibre bioanalytics company.
“TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services,” he said.

Author By Agilex BiolabsPosted on
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced it will showcase its world-class immunoassay and immunobiology services for regulated bioanalysis at Bio-Europe 2021.

Author By Agilex BiolabsPosted on
Demand for APAC clinical trials is still on the rise as COVID numbers continue to fall across the region attracting biotechs wanting to restart stalled or paused clinical trials from around the globe. Indeed Australia recorded zero new cases in the past 25 days.

Author By Agilex BiolabsPosted on
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, today announced the roll-out of the GALEXI™ client portal for real-time study management.

Author By Agilex BiolabsPosted on
Agilex Biolabs is the leading bioanalytical laboratory in Asia-Pacific with the most advanced platforms for sensitive technologies. They include Sciex API 6500+ LC-MS/MS, Sciex API 4000 LC-MS/MS systems; Gyrolab™ Xplore, Luminex MAGPIX xPONENT ™, MSD Quickplex 120 and BD FACSymphony™ A3 20 colour flow cytometry analysers, so we have the capability to deliver any sized project.

Author By Agilex BiolabsPosted on
Register here (free)...

Author By Agilex BiolabsPosted on
Agilex Biolabs, the leading APAC biolabs for biotech clinical trials, announced today the launch of a Client Portal named GALEXI™.
The Agilex Biolabs technology team, with its Microsoft partner, accelerated the launch of GALEXI™ to deliver secure and enhanced communications during continued COVID challenges globally.
The Agilex Biolabs technology team, with its Microsoft partner, accelerated the launch of GALEXI™ to deliver secure and enhanced communications during continued COVID challenges globally.

Author By Agilex BiolabsPosted on
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, congratulates client company Shasqi on the announcement of the first-ever application of click chemistry in humans, with the launch of the Company’s lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development.

Author By Agilex BiolabsPosted on
Title: Development and Validation of a PK Method for Tocilizumab in Both Singlicate and Duplicate on the Gyrolab Platform

Author By Agilex BiolabsPosted on
Agilex Biolabs, Australia’s most advanced specialist bioanalytical laboratory for clinical trials, congratulated client Zelira Therapeutics on their Phase 2 Medicinal Cannabis Insomnia Study.

Author By Agilex BiolabsPosted on
Why Australia is the World’s Leading Early Phase Destination – Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs Increasingly Sponsors are wanting to be actively involved in the core clinical partner selection because they matter to the success of their clinical research.